The growing prevalence of dry eye conditions is increasing demand for products that provide sustained ocular lubrication and symptom relief. Aging populations, screen exposure, contact lens use, and rising awareness are supporting adoption across healthcare settings.
The Dry Eye Products Market is projected to expand from US$6.95 billion in 2023 to US$10.04 billion by 2031, registering a CAGR of 4.7% during 2023–2031. The addressable opportunity is estimated at US$68.74 billion during 2024–2031, reflecting significant potential for manufacturers and healthcare providers.
Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00012323
Rising Geriatric Population Strengthens Product Demand
Dry eye disease is increasingly associated with aging, as tear production and tear-film stability tend to decline with advancing age. The growing global geriatric population is therefore creating a sustained need for artificial tears, prescription therapies, punctal plugs, and other treatment options. The World Health Organization estimates that the population aged 60 years and above will increase from 1 billion in 2020 to 1.4 billion by 2030 and reach approximately 2.1 billion by 2050.
Additional risk factors, including contact lens use, autoimmune disorders, refractive surgeries, systemic medications, and prolonged digital-device exposure, are expanding the patient pool. Increasing awareness of dry eye symptoms and greater access to ophthalmic care are also encouraging patients to seek treatment earlier.
Artificial Tears Lead Product Segment
By product, the industry is segmented into artificial tears, anti-inflammatory drugs, punctal plugs, secretagogues, oral omega supplements, and others. Artificial tears accounted for the largest share of 45.3% in 2023, supported by their broad availability, ease of use, and widespread use for mild to moderate symptoms.
Artificial tears are available in preserved and preservative-free formulations, with selection often influenced by frequency of use and patient sensitivity. Meanwhile, anti-inflammatory drugs are expected to record the fastest growth, with the segment projected to achieve a 5.7% CAGR during 2023–2031. Within this category, corticosteroids are anticipated to demonstrate particularly strong growth, registering a 6.7% CAGR.
By dosage form, eye drops held the leading position in 2023, while gels are projected to grow at the fastest rate, with a 5.2% CAGR. Gel formulations can provide longer ocular retention, supporting their adoption among patients requiring prolonged relief.
OTC Products and Online Pharmacies Gain Momentum
The OTC segment represented the largest share by type, accounting for 58.1% in 2023, and is expected to grow at a 5.1% CAGR through 2031. Easy accessibility and increasing consumer awareness are key factors supporting OTC adoption, particularly for artificial tears and other nonprescription products.
Distribution is categorized into retail pharmacies, hospital pharmacies, and online pharmacies. Retail pharmacies maintained the leading position in 2023 because of their established accessibility and role in routine healthcare purchases. However, online pharmacies are expected to register the fastest growth at a 5.7% CAGR, supported by digital purchasing, home delivery, product availability, and increasing consumer preference for convenient healthcare access.
North America Dominates While Asia Pacific Presents Opportunities
North America held the largest regional share in 2023, accounting for approximately 55% of the global industry. High disease awareness, a growing elderly population, advanced ophthalmic infrastructure, and the frequent introduction of new products contribute to regional leadership. The US is projected to record a 4.9% CAGR during the forecast period.
Europe represents another significant regional market, supported by increasing awareness of dry eye disease, an aging population, and the growing prevalence of ophthalmic disorders. Germany, the UK, France, and Italy remain important markets due to established healthcare systems and demand for ophthalmic treatments.
Asia Pacific is expected to experience strong expansion, registering a 5.1% CAGR. Increasing healthcare expenditure, improving access to ophthalmic services, rising awareness, and a large aging population are creating attractive opportunities across China, India, Japan, and Australia.
Competitive Landscape and Key Players
Companies are focusing on product innovation, portfolio expansion, strategic partnerships, and geographic expansion to strengthen their positions. Key players include:
- Bausch Health Companies Inc.
- Novartis AG
- Johnson & Johnson
- Santen Pharmaceutical Co., Ltd.
- AbbVie Inc.
- OASIS Medical
- URSAPHARM Arzneimittel GmbH
- Rohto Pharmaceutical Co., Ltd.
- OCuSOFT Inc.
- Prestige Consumer Healthcare Inc.
- Farmigea SpA
- Alcon AG
The competitive environment is also being influenced by advances in formulation technologies, preservative-free products, longer-lasting gels, targeted anti-inflammatory therapies, and convenient delivery formats. Companies that can combine clinical effectiveness with improved patient comfort and accessibility are likely to gain competitive advantages.
Interested in Purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00012323
Future Outlook
The Dry Eye Products Market is expected to maintain steady growth through 2031 as demographic changes, lifestyle-related risk factors, greater disease awareness, and advances in ophthalmic treatment continue to expand demand. The transition toward preservative-free formulations, innovative delivery systems, digital pharmacy channels, and targeted prescription therapies will create new opportunities.
Related Report:
1) Drug Discovery Informatics Market Size, Share, and Growth Forecast to 2031
2) Non-Gelatin Empty Capsules Market Size, Trends & Forecast 2031
3) Drug Delivery Devices Contract Manufacturing Market – Size, Share & Forecast by 2034
About Us –
The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.
Contact Us:
Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
Also Available in : Korean German Japanese French Chinese Italian Spanish